The aurora kinase A inhibitor alisertib has demonstrated preclinical and/or clinical activity in several cancer types, including SCLC and other high grade neuroendocrine cancers such as neuroblastoma [34]. The gene discussed is AURKA; the disease is neuroblastoma.